220 related articles for article (PubMed ID: 33784257)
1. Prevention of guanylyl cyclase-B dephosphorylation rescues achondroplastic dwarfism.
Wagner BM; Robinson JW; Lin YW; Lee YC; Kaci N; Legeai-Mallet L; Potter LR
JCI Insight; 2021 May; 6(9):. PubMed ID: 33784257
[TBL] [Abstract][Full Text] [Related]
2. Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth.
Shuhaibar LC; Kaci N; Egbert JR; Horville T; Loisay L; Vigone G; Uliasz TF; Dambroise E; Swingle MR; Honkanen RE; Biosse Duplan M; Jaffe LA; Legeai-Mallet L
JCI Insight; 2021 May; 6(9):. PubMed ID: 33986191
[TBL] [Abstract][Full Text] [Related]
3. Dephosphorylation is the mechanism of fibroblast growth factor inhibition of guanylyl cyclase-B.
Robinson JW; Egbert JR; Davydova J; Schmidt H; Jaffe LA; Potter LR
Cell Signal; 2017 Dec; 40():222-229. PubMed ID: 28964968
[TBL] [Abstract][Full Text] [Related]
4. A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B.
Robinson JW; Dickey DM; Miura K; Michigami T; Ozono K; Potter LR
Bone; 2013 Oct; 56(2):375-82. PubMed ID: 23827346
[TBL] [Abstract][Full Text] [Related]
5. Male mice with elevated C-type natriuretic peptide-dependent guanylyl cyclase-B activity have increased osteoblasts, bone mass and bone strength.
Robinson JW; Blixt NC; Norton A; Mansky KC; Ye Z; Aparicio C; Wagner BM; Benton AM; Warren GL; Khosla S; Gaddy D; Suva LJ; Potter LR
Bone; 2020 Jun; 135():115320. PubMed ID: 32179168
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
[TBL] [Abstract][Full Text] [Related]
7. Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
Matsushita M; Hasegawa S; Kitoh H; Mori K; Ohkawara B; Yasoda A; Masuda A; Ishiguro N; Ohno K
Endocrinology; 2015 Feb; 156(2):548-54. PubMed ID: 25456072
[TBL] [Abstract][Full Text] [Related]
8. Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
Lee YC; Song IW; Pai YJ; Chen SD; Chen YT
Sci Rep; 2017 Feb; 7():43220. PubMed ID: 28230213
[TBL] [Abstract][Full Text] [Related]
9. Guanylyl Cyclase-B Dependent Bone Formation in Mice is Associated with Youth, Increased Osteoblasts, and Decreased Osteoclasts.
Wagner BM; Robinson JW; Prickett TCR; Espiner EA; Khosla S; Gaddy D; Suva LJ; Potter LR
Calcif Tissue Int; 2022 Nov; 111(5):506-518. PubMed ID: 35947145
[TBL] [Abstract][Full Text] [Related]
10. A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3.
Wang Y; Spatz MK; Kannan K; Hayk H; Avivi A; Gorivodsky M; Pines M; Yayon A; Lonai P; Givol D
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4455-60. PubMed ID: 10200283
[TBL] [Abstract][Full Text] [Related]
11. An Fgfr3-activating mutation in immature murine osteoblasts affects the appendicular and craniofacial skeleton.
Biosse Duplan M; Dambroise E; Estibals V; Veziers J; Guicheux J; Legeai-Mallet L
Dis Model Mech; 2021 Apr; 14(4):. PubMed ID: 33737326
[TBL] [Abstract][Full Text] [Related]
12. Dephosphorylation of the NPR2 guanylyl cyclase contributes to inhibition of bone growth by fibroblast growth factor.
Shuhaibar LC; Robinson JW; Vigone G; Shuhaibar NP; Egbert JR; Baena V; Uliasz TF; Kaback D; Yee SP; Feil R; Fisher MC; Dealy CN; Potter LR; Jaffe LA
Elife; 2017 Dec; 6():. PubMed ID: 29199951
[TBL] [Abstract][Full Text] [Related]
13. Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.
Xie Y; Su N; Jin M; Qi H; Yang J; Li C; Du X; Luo F; Chen B; Shen Y; Huang H; Xian CJ; Deng C; Chen L
Hum Mol Genet; 2012 Sep; 21(18):3941-55. PubMed ID: 22634226
[TBL] [Abstract][Full Text] [Related]
14. Skeletal Characterization of the Fgfr3 Mouse Model of Achondroplasia Using Micro-CT and MRI Volumetric Imaging.
Shazeeb MS; Cox MK; Gupta A; Tang W; Singh K; Pryce CT; Fogle R; Mu Y; Weber WD; Bangari DS; Ying X; Sabbagh Y
Sci Rep; 2018 Jan; 8(1):469. PubMed ID: 29323153
[TBL] [Abstract][Full Text] [Related]
15. FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism.
He L; Shobnam N; Wimley WC; Hristova K
J Biol Chem; 2011 Apr; 286(15):13272-81. PubMed ID: 21324899
[TBL] [Abstract][Full Text] [Related]
16. A loss-of-function mutation in natriuretic peptide receptor 2 (Npr2) gene is responsible for disproportionate dwarfism in cn/cn mouse.
Tsuji T; Kunieda T
J Biol Chem; 2005 Apr; 280(14):14288-92. PubMed ID: 15722353
[TBL] [Abstract][Full Text] [Related]
17. Effect of the G375C and G346E achondroplasia mutations on FGFR3 activation.
He L; Serrano C; Niphadkar N; Shobnam N; Hristova K
PLoS One; 2012; 7(4):e34808. PubMed ID: 22529939
[TBL] [Abstract][Full Text] [Related]
18. PTH has the potential to rescue disturbed bone growth in achondroplasia.
Ueda K; Yamanaka Y; Harada D; Yamagami E; Tanaka H; Seino Y
Bone; 2007 Jul; 41(1):13-8. PubMed ID: 17466614
[TBL] [Abstract][Full Text] [Related]
19. Catalytically Active Guanylyl Cyclase B Requires Endoplasmic Reticulum-mediated Glycosylation, and Mutations That Inhibit This Process Cause Dwarfism.
Dickey DM; Edmund AB; Otto NM; Chaffee TS; Robinson JW; Potter LR
J Biol Chem; 2016 May; 291(21):11385-93. PubMed ID: 26980729
[TBL] [Abstract][Full Text] [Related]
20. Severe achondroplasia due to two de novo variants in the transmembrane domain of FGFR3 on the same allele: A case report.
Nagata T; Matsushita M; Mishima K; Kamiya Y; Kato K; Toyama M; Ogi T; Ishiguro N; Kitoh H
Mol Genet Genomic Med; 2020 Mar; 8(3):e1148. PubMed ID: 31975530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
